Research into Chronic obstructive pulmonary disease spans multiple therapeutic approaches and trial phases.

13 total trials for this combination

Showing top 10 of 13 trials

Trials

NCT ID	Title	Status	Phase
NCT06208306	A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD	ACTIVE_NOT_RECRUITING	PHASE3
NCT05878769	A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)	RECRUITING	PHASE3
NCT04751487	Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)	COMPLETED	—
NCT00845728	Exacerbation Study	COMPLETED	PHASE3
NCT04751487	Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)	COMPLETED	—
NCT05612035	Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD	ACTIVE_NOT_RECRUITING	—
NCT04456673	Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation	COMPLETED	PHASE3
NCT00206154	A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients	COMPLETED	PHASE3
NCT04751487	Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)	COMPLETED	—
NCT04751487	Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)	COMPLETED	—

Related Pages

All Chronic obstructive pulmonary disease trials All trials in Durban, South Africa